This may reduce waste and costs, optimize convenience and workflow and reduce the chance for preparation error-all of which support quality patient care.īradycardia: Neostigmine, a component of PREVDUO ™, is associated with bradycardia. Ready-to-use, or RTU, products streamline operations for hospitals by eliminating the need to prepare or transfer the product before patient administration. 'Following the development and FDA approval of Prevduo ™, we're pleased to partner with Endo and tap into Endo's proven capabilities in commercializing injectable solutions, including ready-to-use products,' said Ajay Singh, Founder and CEO of Slayback Pharma.

'We're proud to partner with Slayback to bring this critical care product to market and help hospitals deliver quality patient care.' 'Prevduo ™ further strengthens our commitment to supporting healthcare providers and their patients through ready-to-use products that streamline operations,' said Scott Sims, Senior Vice President and General Manager, Injectable Solutions & Generics at Endo. Neostigmine is always administered in conjunction with glycopyrrolate, and currently, its administration requires two syringes. as single, active ingredient drug products. Both neostigmine methylsulfate and glycopyrrolate have been approved in the U.S. When launched, Prevduo ™ will be the first and only FDA-approved neostigmine–glycopyrrolate combination product in the U.S. The Attorney General believes the complaint should be made available to the public in its entirety and efforts to keep it confidential will only prolong and diminish Endo’s accountability for its conduct.Endo will commercialize Prevduo ™ through its Par Sterile Products business and expects to launch the product in June 2023. The order sealed by the judge allows the seal to expire in 10 days unless Endo acts to extend it. The Attorney General requested the complaint be filed under a temporary seal because Endo claims the information produced during the State’s investigation is confidential. Endo provided significant funding to other third-party groups and subsequently relied on material generated by those groups without disclosing the financial relationship. The State also has reason to believe Endo used the recommendations and educational materials of third-party groups like the American Pain Foundation without disclosing that Endo was by far the biggest donor to the Foundation and provided more than half of its total funding. The Complaint alleges that Endo also knew the dangers of its opioid products, including increased risks of respiratory depression and death in elderly patients, and failed to clearly disclose those risks while it specifically targeted patients in that age group. It did this despite evidence to the contrary, including the FDA’s explicit rejection of Endo’s claim that Opana ER was resistant to abuse as well as overwhelming evidence that Opana ER was being abused throughout Tennessee.

The allegations in the State’s 180-page complaint detail how Endo deceptively marketed its opioid products as being less addictive and more effective than others on the market. “Endo has repeatedly refused to take responsibility for its unconscionable conduct, which is why we are taking this action.” “Our Office has conducted an extensive investigation into Endo’s unlawful marketing practices which included targeting vulnerable populations like the elderly,” said Tennessee Attorney General Herbert H. The State’s lawsuit, filed in Knoxville, alleges Endo violated the Tennessee Consumer Protection Act and contributed to a devastating public health crisis in Tennessee. (Endo) for making unlawful and false claims about the safety and benefits of its opioid products. Slatery III today sued Endo Pharmaceuticals and Endo Health Solutions Inc.

Here are details from the news release by Attorney General Herbert Slatery’s office:Īttorney General Herbert H. The AG’s office says Endo violated the Tennessee Consumer Protection Act and contributed to a devastating health crisis in Tennessee. The Tennessee Attorney General is suing Endo for making unlawful and false claims about the safety and benefits of its opioid products. TN Attorney General sues opioid maker Endo Pharmaceuticals (photo courtesy Times News)Įndo Pharmaceuticals, the same company which was at the center of a $193 million settlement with one of James Hoyer’s whistleblower clients, is now facing another major legal battle.

Endo pharma slalom